Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation - PubMed (original) (raw)
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation
Jin Kyung Rho et al. Mol Cancer Ther. 2010 Dec.
Abstract
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) produce an initially dramatic response in lung cancer patients harboring a mutation in the EGFR gene, development of acquired resistance is almost inevitable. A secondary mutation of threonine 790 (T790M) is associated with approximately half of the cases of acquired resistance. This study investigated whether the addition of silibinin to therapy with gefitinib or erlotinib could overcome T790M-mediated drug resistance considering that silibinin has various antitumor effects, including EGFR modulation. Silibinin selectively reduced the activity of the EGFR family (EGFR, ErbB2, and ErbB3) through the inhibition of receptor dimerization in lung cancer cells with EGFR mutations, but not in those harboring the wild type. In primary and acquired resistant cells with T790M, addition of silibinin enhanced the ability of EGFR-TKIs to downregulate EGFR signals and to inhibit cell growth. Similarly, the combination of silibinin and erlotinib effectively suppressed tumor growth in erlotinib resistance-bearing PC-9 xenografts. The results indicate that the addition of silibinin to EGFR-TKIs is a promising strategy to overcome T790M-mediated drug resistance.
©2010 AACR.
Similar articles
- Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Nakagawa T, et al. Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25. Mol Cancer Ther. 2012. PMID: 22844075 - Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K. Takezawa K, et al. Mol Cancer Ther. 2010 Jun;9(6):1647-56. doi: 10.1158/1535-7163.MCT-09-1009. Epub 2010 Jun 8. Mol Cancer Ther. 2010. PMID: 20530710 - Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA. Corominas-Faja B, et al. Cell Cycle. 2013 Nov 1;12(21):3390-404. doi: 10.4161/cc.26417. Epub 2013 Sep 17. Cell Cycle. 2013. PMID: 24047698 Free PMC article. - Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
Xu Y, Liu H, Chen J, Zhou Q. Xu Y, et al. Cancer Biol Ther. 2010 Apr 15;9(8):572-82. doi: 10.4161/cbt.9.8.11881. Epub 2010 Apr 26. Cancer Biol Ther. 2010. PMID: 20404520 Review. - Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
Eck MJ, Yun CH. Eck MJ, et al. Biochim Biophys Acta. 2010 Mar;1804(3):559-66. doi: 10.1016/j.bbapap.2009.12.010. Epub 2009 Dec 22. Biochim Biophys Acta. 2010. PMID: 20026433 Free PMC article. Review.
Cited by
- Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.
Mateen S, Raina K, Agarwal R. Mateen S, et al. Nutr Cancer. 2013;65 Suppl 1(0 1):3-11. doi: 10.1080/01635581.2013.785004. Nutr Cancer. 2013. PMID: 23682778 Free PMC article. Review. - Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.
Bosch-Barrera J, Martin-Castillo B, Buxó M, Brunet J, Encinar JA, Menendez JA. Bosch-Barrera J, et al. J Clin Med. 2020 Jun 7;9(6):1770. doi: 10.3390/jcm9061770. J Clin Med. 2020. PMID: 32517353 Free PMC article. - Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong JH. Gu HR, et al. Clin Mol Hepatol. 2015 Mar;21(1):49-59. doi: 10.3350/cmh.2015.21.1.49. Epub 2015 Mar 25. Clin Mol Hepatol. 2015. PMID: 25834802 Free PMC article. - Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.
Koltai T, Fliegel L. Koltai T, et al. J Evid Based Integr Med. 2022 Jan-Dec;27:2515690X211068826. doi: 10.1177/2515690X211068826. J Evid Based Integr Med. 2022. PMID: 35018864 Free PMC article. Review. - IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.
Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Torres-Garcia VZ, Corominas-Faja B, Cuyàs E, Bonavia R, Visa J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA. Vazquez-Martin A, et al. Sci Rep. 2013;3:2560. doi: 10.1038/srep02560. Sci Rep. 2013. PMID: 23994953 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous